1986 | OriginalPaper | Buchkapitel
5-Fluorouracil Plus Thymidine or Leucovorin by Continuous I.V. Infusion in the Treatment of Advanced Colorectal Carcinoma
verfasst von : Fabio Trave, Youcef M. Rustum
Erschienen in: Clinical Applications of Continuous Infusion Chemotherapy and Concomitant Radiation Therapy
Verlag: Springer US
Enthalten in: Professional Book Archive
Aktivieren Sie unsere intelligente Suche um passende Fachinhalte oder Patente zu finden.
Wählen Sie Textabschnitte aus um mit Künstlicher Intelligenz passenden Patente zu finden. powered by
Markieren Sie Textabschnitte, um KI-gestützt weitere passende Inhalte zu finden. powered by
5-Fluorouracil (FUra) has been the drug of choice in the treatment of colorectal cancers (1,2), and it is widely utilized in a variety of other malignancies (3). FUra exerts its antiproliferative effect following metabolic activation to various nucleotides (Chart 1). 5-Fluorouridine triphosphate (FUTP), due to its resemblance with uridine triphosphate (UTP), is incorporated into RNA (4–7); the consequence of this incorporation is the production of fraudulent mRNA, rRNA and tRNA which can ultimately cause cell death. The other proposed mechanism for FUra cytotoxicity is the inhibition of thymidylate synthetase (dTMP-S) by 5-fluorodeoxyuridine monophosphate (FdUMP) (8–11), leading to decreased thymidine triphosphate (dTTP) pools and to inhibition of DNA synthesis. The biochemical mechanism by which FdUMP binds to the dTMP-S involves a cofactor, N5,10methylene tetrahydrofolic acid (N5,10CH2FH4). Santi et al. have calculated that the dissociation constant (Kd) of the ternary complex FdUMP-dTMP-SN5,10CH2FH4, is of the order of 5×10-11M. In absence of the reduced folate cofactor, FdUMP binding to dTMP-S is relatively weak, with a Kd of about 10-5M (9). An additional proposed mechanism of cytotoxicity of FUra is its incorporation into DNA (12–15). To date, little is known about the biological significance of this finding.